Stem Cell Breakthrough: Ryoncil® and the Fight Against a Deadly Childhood Disease
Mesoblast, a leader in cell-based therapies, announced that its product Ryoncil® received coverage from the Centers for Medicare and Medicaid Services (CMS). This agreement ensures access to this newly FDA-approved mesenchymal stromal cell therapy for children with steroid-refractory acute graft versus host disease (SR-aGvHD) covered by Medicaid. Consequently, the first three pediatric patients will begin receiving Ryoncil® treatment this […]
FDA Accepts BLA for Ryoncil: First Allogeneic “Off-the-Shelf” Cellular Medicine and First Cell Therapy for Children in the United States
In a significant milestone for pediatric medicine, the FDA has accepted Mesoblast’s Biologics License Application (BLA) for Ryoncil® (remestemcel-L), aimed at treating children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD). This acceptance marks a crucial step towards the approval of the first allogeneic “off-the-shelf” cellular medicine in the United States, and the first cell therapy for […]